Gabriel Rubió is a Market Access profesional. He holds more than 7 years of experience in Life Sciences strategy and Market Access functions within the pharmaceutical industry, where he has been managing products within the CV prevention space.
He is interested in defining how the Clinical performance of medications reflect in improvement in the quality of care and efficiency in the different health systems.
Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control
Event: ESC Preventive Cardiology 2021
Topic: Health Economics
Session: Rapid fire abstracts - Secondary Prevention and Rehabilitation
ESC 365 is supported by
